Breast cancer (BC) remains one of the leading causes of cancer-related mortality in women worldwide. Recent studies have explored the role of myokines, signaling proteins released during muscle contraction, in regulating tumor growth, metastasis, and the tumor microenvironment. This study investigates the correlation between myokines and breast cancer progression, focusing on the role of irisin and decorin. The study was conducted at two oncology centers in Baghdad, Iraq, from May to December 2022. A total of 88 Iraqi women, aged 20-70, were enrolled in the study across six groups: healthy controls (G1) and women with different treatment regimens (G2-G6). Blood samples were collected after fasting, and myokine concentrations were measured using ELISA. Additionally, histopathological examinations were performed on tissue biopsies to assess the presence of lobular carcinoma in situ (LCIS). The study found significant differences in myokine concentrations across the groups. Irisin levels were highest in the metastatic group (G6), while decorin levels showed significant variations across the different patient groups. Histological analysis revealed characteristic changes of LCIS, including irregular lobular structures, hyperplasia, and inflammatory cell infiltration. This study highlights the potential role of myokines, particularly irisin and decorin, as biomarkers for breast cancer progression. Elevated irisin levels in advanced stages suggest its involvement in tumor development and metastasis.
| Attachment | Size |
|---|---|
 05_67-81.pdf | 1.17 MB |
